Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
The current Eli Lilly(LLY) stock price is $1,029.44, with a market capitalization of 987.12B. The stock trades at a price-to-earnings (P/E) ratio of 50.82 and offers a dividend yield of 58.4%.
As of 2025-12-13, Eli Lilly(LLY) stock has fluctuated between $1,003.50 and $1,029.93. The current price stands at $1,029.44, placing the stock +2.6% above today's low and -0.0% off the high.
Eli Lilly(LLY) shares are trading with a volume of 3.28M, against a daily average of 3.26M.
In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.
In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.
LLY News
Key Points With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly r...
Wondering if Eli Lilly is still worth buying after its monster run, or if the upside has already been priced in? You are not alone, and that is exactly what thi...
Eli Lilly and Co. (NYSE:LLY) on Friday shared updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for previously treated breast cancer pat...
Analyst ratings
74%
of 31 ratingsMore LLY News
...
Eli Lilly (LLY) and Company announced updated results from the Phase 3 EMBER-3 study of Inluriyo, an oral estrogen receptor antagonist, in patients with estroge...
Technology Eli Lilly Rises, Again, After EMA Recommends Mounjaro For Children As Young As 10 Licensing Europe's drug regulator on Friday recommended extending t...
Media reports say that the U.S. Food and Drug Administration (FDA) is being pushed internally to fast-track approval of Eli Lilly’s (LLY) experimental weight-lo...
Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s...
The FDA is accelerating its review of Eli Lilly’s (LLY) experimental weight loss pill, reducing the internal evaluation period from 60 days to one week under a...
This week's dividend activity included increased payouts from Eli Lilly (LLY) and Mastercard (MA) as well as declarations from companies such as JPMorgan Chase...
